



## Trichostatin A

## Data Sheet

<b>Catalog Number:</b>	MC11103	<b>Product Type:</b>	Small Molecule
<b>Bio-Activity:</b>	HDAC inhibitor	<b>CAS #:</b>	58880-19-6
<b>Research Categories:</b>	Epigenetics, stem cells, cell death, infectious disease, cancer	<b>Chemical Name:</b>	(2E,4E,6R)-7-(4-(Dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide
<b>Solubility:</b>	Soluble in DMSO (up to 20 mg/ml), or in Ethanol (up to 3 mg/ml).	<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>22</sub> N <sub>2</sub> O <sub>3</sub>
<b>Purity:</b>	> 98%	<b>Molecular Weight:</b>	302.4
<b>Format:</b>	Powder	<b>Ship Temp:</b>	Ambient
<b>Storage:</b>	-20°C		

### Application Notes

#### Description/Data:

Potent and selective histone deacetylase (HDAC) inhibitor (K<sub>i</sub> = 3.4 nM). Induces reversion of ras transformed cells to normal morphology [1]. Trichostatin A induces dedifferentiation of primordial germ cells into embryonic germ cells [2]. Cell permeable and active in vivo [3]. Decreased global chromatin condensation increasing gene-editing efficiency 2-4X [4]. Part of the CRISPY mix for increasing precise gene editing [5].

#### References:

- 1) Yoshida et al. (1990), Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A ; J. Biol. Chem., 265 17174
- 2) Futamura et al. (1995), Trichostatin A inhibits both ras-induced neurite outgrowth of PC12 cells and morphological transformation of NIH3T3 cells; Oncogene, 10 1119
- 3) Durcova-Hills et al. (2008), Reprogramming Primordial Germ Cells into Pluripotent Stem Cells; PLoS-One, 3 e3531
- 4) Molugu et al. (2023), Trichostatin A for Efficient CRISPR-Cas9 Gene Editing of Human Pluripotent Stem Cells; CRISPR J., 6 473

### FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

5) Riesenberg and Maricic (2018), Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells; Nat. Commun., 9 2165

## *FOR RESEARCH USE ONLY*

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

---

[www.neuromics.com](http://www.neuromics.com)

Neuromics Antibodies • 5325 West 74<sup>th</sup> Street, Suite 8 • Edina, MN 55439  
phone 866-350-1500 • fax 612-677-3976 • e-mail: [pshuster@neuromics.com](mailto:pshuster@neuromics.com)